NCT06160752View on ClinicalTrials.gov

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid TumorMetastatic Cholangiocarcinoma
Interventions
DRUG

Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.

DRUG

Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles

TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.

Trial Locations (4)

43210

RECRUITING

The Ohio State University, Columbus

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

94143

RECRUITING

University of California San Francisco (UCSF), San Francisco

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Tyra Biosciences, Inc

INDUSTRY